Absorption → distribution (blood, fat, crossing the blood-brain barrier) → metabolism (liver enzymes, e.g., CYP family) → elimination.

Speed and route (smoking, IV, oral, intranasal) change peak concentration and cellular exposure — faster peaks usually give stronger reinforcing effects.

Receptor agonism/antagonism — directly activate or block receptors (e.g., opioids activate mu receptors; naloxone blocks them).

Transporter inhibition — block reuptake transporters (e.g., cocaine blocks DAT, SERT, NET → increases synaptic monoamines).

Ion channel modulation — change membrane excitability (alcohol and benzodiazepines enhance GABA_A receptor chloride currents; some anesthetics modulate ion channels).

Enzyme inhibition/activation — e.g., MAO inhibitors alter monoamine breakdown.

Intracellular second-messenger cascades — altered receptor activation changes cAMP, PKA, MAPK pathways, which change cellular function acutely and chronically.

Immediate changes in membrane potential and neurotransmitter levels → altered firing rates.

Acute increases in extracellular dopamine in reward circuits (ventral tegmental area → nucleus accumbens) that signal reward/salience.

Receptor regulation: receptors can be downregulated, upregulated, or desensitized (less responsive) after chronic exposure.

Synaptic plasticity: changes in synaptic strength via insertion/removal of AMPA receptors (LTP/LTD), structural changes to dendritic spines.

Gene expression & epigenetics: chronic drug exposure alters transcription factors (e.g., ΔFosB, CREB) and can change chromatin structure — this changes how neurons respond long after the drug is gone.

Mitochondrial stress & oxidative damage: some drugs produce cellular stress that damages neurons, cardiac cells, liver cells.

Glial & immune activation: microglia and astrocytes respond to drug-induced damage or inflammation, altering neurotransmitter clearance and synaptic support.

Liver: many drugs are hepatically metabolized — risk of hepatitis, enzyme induction, or hepatotoxicity (e.g., acetaminophen with alcohol).

Heart & vasculature: stimulants can cause arrhythmia, cardiomyopathy; some drugs cause vasoconstriction or ischemia.

Immune system & infection risk: IV use increases infection risk; some drugs suppress immunity.

Blood–brain barrier & neuroinflammation: chronic use can alter BBB permeability and increase neuroinflammation.

Key pathway: VTA → nucleus accumbens (NAc) → prefrontal cortex (PFC). Drugs hijack this circuit, producing strong dopamine signals that mark drug use as highly salient.

Over time, “wanting” (incentive salience) increases for drug-related cues even if “liking” (pleasure) decreases.

Chronic drug use weakens prefrontal cortical control (planning, impulse control, future thinking), leading to poor decision-making and increased impulsivity.

The balance shifts from goal-directed behavior to habitual/compulsive behavior (dorsal striatum taking over).

Chronic use recruits stress systems (CRF, noradrenaline) and produces negative emotional states in withdrawal → drug use becomes a way to avoid negative feelings (negative reinforcement).

Cues associated with drug use (people, places, paraphernalia) become powerful triggers through classical conditioning → cue exposure produces physiological craving and drug-seeking.

This is learning at the neural level: synaptic strengthening of cue–reward associations.

Escalation of use, prioritizing drug over responsibilities, social withdrawal, increased risk-taking, mood instability, poor impulse control, and repeated relapse cycles.

Receptor downregulation or desensitization, changes in receptor signaling pathways.

Example: opioid receptors internalize/diminish responsiveness, so the same dose produces less analgesia.

Enzyme induction (e.g., chronic alcohol can induce some CYP enzymes), so less drug reaches targets.

Users learn to compensate for drug effects (appear “normal” under influence), or performance improves via practice despite intoxication.

Tolerance can be stronger in environments where drug use usually occurs (classical conditioning of physiological compensatory responses). This is why using the same dose in a novel context raises overdose risk.

“Cells that fire together, wire together.” Repeated co-activation of pathways strengthens synapses via NMDA receptor-dependent long-term potentiation (LTP), AMPA receptor insertion, and structural spine changes.

Dopamine signals prediction errors (better/worse than expected outcomes) and gates synaptic plasticity — it stamps in associations between actions/cues and outcomes.

Drugs produce large, often unphysiological dopamine signals → strong reinforcement of drug-taking actions and cues.

Pavlovian: neutral cues become conditioned stimuli that trigger physiological and motivational responses (craving).

Operant: drug-taking reinforced by positive (pleasure) or negative (relief from withdrawal/stress) reinforcement.

Early, goal-directed drug use mediated by PFC and ventral striatum; with repetition, control shifts toward dorsal striatum → behaviors become automatic/habitual.

This is why relapse can occur without conscious “choice” — habits are powerful.

Memories of drug experiences consolidate into long-term memory and can be reconsolidated (updated) when reactivated — a possible therapeutic target for weakening maladaptive associations.

After cessation, many neuroadaptations are reversible: receptor densities normalize, synaptic remodeling continues, PFC function can recover (weeks–months), and new learning is possible.

Some changes (epigenetic marks, structural damage) may persist longer — recovery is variable but often substantial.

Opioid use disorder: methadone, buprenorphine (partial agonist), naltrexone (antagonist) — reduce cravings/withdrawal and overdose risk.

Alcohol use disorder: naltrexone (reduces reward/craving), acamprosate (stabilizes glutamate/GABA), disulfiram (aversive).

Nicotine dependence: NRT, varenicline, bupropion.

Benzodiazepine or alcohol withdrawal: tapering strategies or benzodiazepines under medical supervision.

Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), Contingency Management, Family Therapy, 12-step/sober mutual aid, and skills training (emotion regulation, relapse prevention).

These target learning mechanisms (new reinforcement contingencies, cue management, cognitive control).

Cue-exposure (with relapse prevention), cognitive restructuring, mindfulness-based relapse prevention, stress management, and behavioral replacement strategies.

Sleep, nutrition, regular physical activity (increases BDNF and supports neurogenesis), social support, structured routine, vocational/meaningful activity.

Treat co-occurring mental health disorders (depression, anxiety, PTSD) — they contribute to relapse risk.

Naloxone for opioid overdose; supervised consumption services where available; education on safer use when abstinence is not immediately achievable.

Recognize relapse as a common part of the disorder — plan for it (safety plan, support contacts, medication adjustments).

Some improvements begin quickly (days–weeks): sleep, mood, cognitive clarity.

Executive function and cue resistance often improve over months to a year or more.

Long-term recovery is common with sustained treatment and support — the brain retains plasticity throughout life.